Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck revises Arcoxia NDA

Executive Summary

Merck is withdrawing the NDA for its COX-2 inhibitor Arcoxia (etoricoxib) and refiling with additional ankylosing spondylitis efficacy data. "Merck believes the new data, along with the data previously submitted, will provide a fuller picture of the product's safety and efficacy and will position it more favorably for approval in the U.S." Additional studies are not needed; Merck has the ankylosing spondylitis data on hand. Merck filed the Vioxx follow-on Oct. 11. Arcoxia may be reviewed by FDA's Arthritis Advisory Committee in mid-May (1"The Pink Sheet" March 4, In Brief)...

You may also be interested in...

Novartis Prexige Is “Not Approvable;” COX-2 Launch At Least Two Years Away

The liver safety profile of Novartis' Prexige appears to be one factor behind FDA's request for additional studies on the COX-2 inhibitor prior to approval in osteoarthritis and acute pain

Enbrel Ankylosing Spondylitis sBLA Clears FDA Cmte.; Modifying Claim Next

Sponsors seeking a disease-modifying claim for an ankylosing spondylitis indication should assess the radiographic progression of the disease, FDA's Arthritis Advisory Committee agreed during its June 24 review of Amgen/Wyeth's Enbrel

Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events

Merck will conduct a 6,000-patient study of Arcoxia focusing on patient discontinuations due to gastrointestinal adverse events

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts